Foolish Forecast: Lockheed As Death Star

Recs

4

Earnings season opens with a bang this week -- the nation's arms makers form ranks and belt out their earnings stats for fiscal Q4 2007. United Technologies (NYSE: UTX) and General Dynamics (NYSE: GD) reported for reveille this morning, and before the month is through, we'll have heard from 'most everybody who's anybody in defense contracting.

Today, we've got Lockheed Martin (NYSE: LMT) on our radar. So let's examine where it's been, where it's going, and what Lockheed has in common with Star Wars' Death Star.

What analysts say:

  • Buy, sell, or waffle? Twenty analysts keep Lockheed on their radar. Twelve rate it a buy, and eight say hold.
  • Revenue. On average, they're looking for flat quarterly sales of about $10.8 billion.
  • Earnings. Profits may eke out a 1% increase to $1.70 per share.

What management says:
Citing "double-digit growth in sales and operating earnings for every business segment" in Q3, CEO Bob Stevens argued that investors should love Lockheed for its "consistently strong operational and financial performance." That wasn't the case last quarter, however, as investors peered past fiscal 2007 performance and pondered the perils the future might hold -- namely, a slowdown in F-16 sales and a lull in new business pending large-scale purchases of Lockheed's new F-35 Lightning II warplane.

What management does:
Which is a crying shame, because it means Lockheed isn't getting the respect it deserves for admirable performance in years past. Gross and net margins have been on the rise for more than 18 months now, and the operating margin for more than a year -- putting the company neck-and-neck with Raytheon (NYSE: RTN) and maintaining its sizeable lead over archrival Boeing (NYSE: BA) in operating profitability. Yet as Lockheed expanded its net margins 16% over the past 12 months, the stock gained a mere 5%.

Margins

6/06

9/06

12/06

3/07

6/07

9/07

Gross

9.3%

9.5%

9.9%

10.1%

10.4%

10.7%

Operating

8.1%

7.6%

8.6%

9.0%

9.3%

10.0%

Net

5.6%

6.1%

6.4%

6.6%

7.0%

7.1%

All data courtesy of Capital IQ, a division of Standard & Poor's. Data reflects trailing-12-month performance for the quarters ended in the named months.

One Fool says:
Are investors overreacting to the F-16 fears? I'm not so sure. This earnings season, I'm running down the "backlog" numbers at all of the major defense contractors, in hopes of finding clues to what their futures might hold. While Lockheed isn't as shareholder-friendly as contractors like Northrop Grumman (NYSE: NOC) or SAIC (NYSE: SAI), which break out the funded and unfunded portions of their backlog, it does give us the "total" of these two sums. Let's compare how Lockheed's backlog has been moving relative to its sales:

Q3 2005

Q3 2006

Q3 2007

Total backlog

$69.1 billion

$77.9 billion

$72.7 billion

YTD revenue

$27.0 billion

$28.8 billion

$31.0 billion

To paraphrase Grand Moff Tarkin, I suspect investors may be correctly estimating the risk of a stall-out at Lockheed. As you can see, sales have grown about 15% and the backlog has grown about 5% over the past two years. Worse, backlog actually declined between Q3 2006 and Q3 2007. As backlog by its very definition represents potential "future sales," what we're seeing here is that Lockheed's past shines brighter than its future. Or as Death Star Commander No. 1 might have put it: "We've analyzed their attack, sir, and there is a danger."

Just in case things get worse before they get better, I'd suggest you keep your ship standing by.

Read up on recent Lockheed news in:

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 558645, ~/Articles/ArticleHandler.aspx, 11/10/2009 7:34:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

11/9/2009 4:00 PM
BA $51.35 Up +1.67 +3.36%
The Boeing Company CAPS Rating: ***
RTN $48.17 Up +0.60 +1.26%
Raytheon Company CAPS Rating: ****
GD $67.31 Up +1.73 +2.64%
General Dynamics C… CAPS Rating: ****
SAI $18.52 Up +0.03 +0.16%
SAIC, Inc. CAPS Rating: ****
NOC $53.93 Up +1.56 +2.98%
Northrop Grumman C… CAPS Rating: ****
UTX $66.73 Up +1.66 +2.55%
United Technologie… CAPS Rating: ****
LMT $75.59 Up +1.82 +2.47%
Lockheed Martin Co… CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Biotechnology: Biotechnology uses biological processes to solve problems in such areas as health and medicine, agriculture and manufacturing.

Want to learn more or edit this definition?
Click here to read more!